Edition:
United Kingdom

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

82.34EUR
23 Feb 2018
Change (% chg)

€-0.04 (-0.05%)
Prev Close
€82.38
Open
€82.66
Day's High
€82.78
Day's Low
€81.80
Volume
442,459
Avg. Vol
560,702
52-wk High
€115.20
52-wk Low
€80.92

Latest Key Developments (Source: Significant Developments)

Forty Seven Says Agreement With Merck KGAA To Conduct Clinical Trials For Patients With Ovarian Cancer
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Merck KGAA ::FORTY SEVEN - AGREEMENT WITH MERCK KGAA TO CONDUCT PHASE 1B CLINICAL TRIAL COMBINING HU5F9-G4 WITH AVELUMAB IN PATIENTS WITH OVARIAN CANCER.  Full Article

Juniper Pharmaceuticals Announces ‍Extension Of Supply Agreement For Crinone
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Juniper Pharmaceuticals Inc ::JUNIPER PHARMACEUTICALS ANNOUNCES 4.5-YEAR EXTENSION THROUGH 2024 OF CRINONE® SUPPLY AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY.JUNIPER PHARMACEUTICALS INC - ‍EXTENSION OF SUPPLY AGREEMENT FOR CRINONE WITH AFFILIATE OF MERCK KGAA.JUNIPER PHARMACEUTICALS INC - ‍AMENDED AGREEMENT EXTENDS SUPPLY TERM AN ADDITIONAL 4.5 YEARS AND AT LEAST THROUGH TO DECEMBER 31, 2024​.  Full Article

Juniper Pharmaceuticals Outlines Strategic Priorities For 2018 And Reports Recent Portfolio Progress
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Juniper Pharmaceuticals Inc ::JUNIPER PHARMACEUTICALS OUTLINES STRATEGIC PRIORITIES FOR 2018 AND REPORTS RECENT PORTFOLIO PROGRESS.JUNIPER PHARMACEUTICALS INC - ON TRACK TO BE CASH FLOW POSITIVE IN 2018.JUNIPER PHARMACEUTICALS INC - CONTINUED "STRONG" DOUBLE-DIGIT REVENUE GROWTH FOR CRINONE AND JPS EXPECTED IN 2018.JUNIPER - ACTIVE DISCUSSIONS WITH MERCK KGAA TO EXTEND CRINONE PROGESTERONE GEL AGREEMENT ARE PROGRESSING.JUNIPER PHARMACEUTICALS INC - PARTNERING OPPORTUNITIES ARE BEING "EXPLORED" FOR JNP-0101, THE OXYBUTYNIN IVR FOR TREATMENT OF OVERACTIVE BLADDER.JUNIPER PHARMACEUTICALS - PARTNERING OPPORTUNITIES ARE BEING "EXPLORED" FOR JNP-0301, A NATURAL PROGESTERONE IVR FOR PREVENTION OF PRE-TERM BIRTH.  Full Article

HTG Molecular Diagnostics Expands Its Collaboration With Merck
Tuesday, 26 Dec 2017 

Dec 26 (Reuters) - Htg Molecular Diagnostics Inc ::HTG MOLECULAR DIAGNOSTICS EXPANDS ITS COLLABORATION WITH MERCK KGAA, DARMSTADT, GERMANY.HTG MOLECULAR - TO DEVELOP CUSTOM PROFILING ASSAY TO SUPPORT BIOMARKER RESEARCH FOR 6 INDICATIONS WITHIN MERCK KGAA'S DRUG DEVELOPMENT PIPELINE.  Full Article

Pfizer Announces Breakthrough Therapy Designation For Avelumab In Combination With Inlyta
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Pfizer Inc ::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR AVELUMAB IN COMBINATION WITH INLYTA® IN ADVANCED RENAL CELL CARCINOMA.PFIZER - BREAKTHROUGH THERAPY DESIGNATION IS BASED ON PRELIMINARY EVALUATION OF CLINICAL DATA FROM JAVELIN RENAL 100 STUDY.  Full Article

FDA grants second breakthrough therapy designation for Avelumab in hard-to-treat cancer​
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Merck Kgaa ::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR AVELUMAB IN COMBINATION WITH INLYTA® IN ADVANCED RENAL CELL CARCINOMA.SAYS ‍SECOND BREAKTHROUGH THERAPY DESIGNATION FOR AVELUMAB IN HARD-TO-TREAT CANCER​.SAYS ‍RENAL CELL CARCINOMA, MOST COMMON FORM OF KIDNEY CANCER, HAS A POOR PROGNOSIS IN ADVANCED STAGE​.SAYS ‍JAVELIN RENAL CLINICAL DEVELOPMENT PROGRAM IS ONGOING, INCLUDING PHASE III FIRST-LINE STUDY​.SAYS ‍FDA) HAS GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR AVELUMAB IN COMBINATION WITH INLYTA(®) (AXITINIB)* FOR TREATMENT-NAÏVE PATIENTS WITH ADVANCED RENAL CELL CARCINOMA​.  Full Article

Merck And Bluebird Bio Sign Supply Agreement For Commercial Production Of Viral Vectors
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - MERCK KGAA ::MERCK AND BLUEBIRD BIO SIGN SUPPLY AGREEMENT FOR COMMERCIAL PRODUCTION OF VIRAL VECTORS.  Full Article

Merck KGaA ‍Receives Approval (Updated Registration) For Cladribine Tablets In Australia​
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Merck KGaA ::SAYS ‍RECEIVES APPROVAL (UPDATED REGISTRATION) FOR CLADRIBINE TABLETS IN AUSTRALIA​.  Full Article

Merck Says Anand Nambiar, MD, Assigned As Head Of Integrated Circuit Materials Unit Of Merck KGaA
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Merck Ltd ::SAYS ANAND NAMBIAR, MD, HAS ACCEPTED NEW ASSIGNMENT AS 'HEAD OF INTEGRATED CIRCUIT MATERIALS' UNIT OF MERCK KGAA.SAYS NAMBIAR TO REMAIN CO'S MD UNTIL MARCH 31, 2018.  Full Article

Merck KGAA, Darmstadt Announces FDA 510(K) Clearance Of Genea Biomedx’S Fertility Benchtop Incubator Geri
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Merck Kgaa ::MERCK KGAA, DARMSTADT, GERMANY ANNOUNCES FDA 510(K) CLEARANCE OF PARTNER GENEA BIOMEDX’S FERTILITY BENCHTOP INCUBATOR GERI™.MERCK KGAA - U.S. COMMERCIAL AVAILABILITY FOR GERI ‍EXPECTED IN FIRST HALF OF 2018 ​.  Full Article

BRIEF-Emd Serono - Co, Pfizer Canada Announce Health Canada Approval For Bavencio For Treating Metastatic Merkel Cell Carcinoma In Previously Treated Adults

* EMD SERONO - CO, PFIZER CANADA ANNOUNCE HEALTH CANADA APPROVAL FOR BAVENCIO FOR TREATING METASTATIC MERKEL CELL CARCINOMA IN PREVIOUSLY TREATED ADULTS Source text for Eikon: Further company coverage: